Rituximab in renal transplantation

被引:65
作者
Barnett, A. Nicholas R. [1 ,2 ]
Hadjianastassiou, Vassilis G. [1 ,2 ,3 ]
Mamode, Nizam [1 ,2 ]
机构
[1] Guys & St Thomas NHS Fdn Trust, Renal & Transplant Dept, London, England
[2] Kings Coll London, Div Transplant Immunol & Mucosal Biol, London WC2R 2LS, England
[3] Nicosia Gen Hosp, Organ Transplant Ctr, Nicosia, Cyprus
关键词
monoclonal antibodies; CD20; antigens; B-lymphocytes; graft rejection; immunosuppression; kidney transplantation; INCOMPATIBLE KIDNEY-TRANSPLANTATION; ANTIBODY-MEDIATED REJECTION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; ANTIGEN-SPECIFIC IMMUNOADSORPTION; SINGLE-DOSE RITUXIMAB; POSITIVE CROSS-MATCH; B-CELL CLUSTERS; INFECTIOUS COMPLICATIONS; INDUCTION THERAPY; INTRAVENOUS IMMUNOGLOBULIN;
D O I
10.1111/tri.12072
中图分类号
R61 [外科手术学];
学科分类号
摘要
Rituximab is a chimeric anti-CD20 monoclonal antibody that leads to B cell depletion. It is not licensed for use in renal transplantation but is in widespread use in ABO blood group incompatible transplantation. It is an effective treatment for post-transplant lymphoproliferative disorder, and is also used in both HLA antibody incompatible renal transplantation and the treatment of acute rejection. Recent evidence suggests rituximab may prevent the development of chronic antibody mediated rejection. The mechanisms underlying its effects are likely to relate both to long-term effects on plasma cell development and to the impact on B cell modulation of T cell responses. Rituximab (in multiple doses or in combination with other monoclonal antibodies and/or other immunosuppressants) may lead to an increase in infectious complications, although the evidence is not clear. Rarely, the drug can cause a cytokine release syndrome, thrombocytopenia and neutropenia. It has been related to an increased risk of progressive multifocal leucoencephalopathy and, recently, deaths from cardiovascular causes. Trials examining the effects of rituximab in induction therapy for compatible renal transplantation and the treatment of chronic antibody mediated rejection are ongoing. These trials should aid greater understanding of the role of B-cells in the alloresponse to renal transplantation.
引用
收藏
页码:563 / 575
页数:13
相关论文
共 99 条
[1]   Post-transplant lymphoproliferative disorder following renal transplantation: A single-center experience over 40 years [J].
Abe, Toyofumi ;
Ichimaru, Naotsugu ;
Kokado, Yukito ;
Maeda, Tetsuo ;
Kakuta, Yoichi ;
Okumi, Masayoshi ;
Imamura, Ryoichi ;
Nonomura, Norio ;
Isaka, Yoshitaka ;
Takahara, Shiro ;
Okuyama, Akihiko .
INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (01) :48-54
[2]   Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab [J].
Alausa, M ;
Almagro, U ;
Siddiqi, N ;
Zuiderweg, R ;
Medipalli, R ;
Hariharan, S .
CLINICAL TRANSPLANTATION, 2005, 19 (01) :137-140
[3]   Rituximab as treatment for refractory kidney transplant rejection [J].
Becker, YT ;
Becker, BN ;
Pirsch, JD ;
Sollinger, HW .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (06) :996-1001
[4]   Successful Treatment of Chronic Antibody-Mediated Rejection With IVIG and Rituximab in Pediatric Renal Transplant Recipients [J].
Billing, Heiko ;
Rieger, Susanne ;
Ovens, Joerg ;
Suesal, Caner ;
Melk, Anette ;
Waldherr, Ruediger ;
Opelz, Gerhard ;
Toenshoff, Burkhard .
TRANSPLANTATION, 2008, 86 (09) :1214-1221
[5]   IL-10 produced by activated human B cells regulates CD4+ T-cell activation in vitro [J].
Bouaziz, Jean-David ;
Calbo, Sebastien ;
Maho-Vaillant, Maud ;
Saussine, Anne ;
Bagot, Martine ;
Bensussan, Armand ;
Musette, Philippe .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2010, 40 (10) :2686-2691
[6]   Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: Report of 230 cases from the French Registry [J].
Caillard, S. ;
Lelong, C. ;
Pessione, F. ;
Moulin, B. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (11) :2735-2742
[7]   Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project [J].
Carson, Kenneth R. ;
Evens, Andrew M. ;
Richey, Elizabeth A. ;
Habermann, Thomas M. ;
Focosi, Daniele ;
Seymour, John F. ;
Laubach, Jacob ;
Bawn, Susie D. ;
Gordon, Leo I. ;
Winter, Jane N. ;
Furman, Richard R. ;
Vose, Julie M. ;
Zelenetz, Andrew D. ;
Mamtani, Ronac ;
Raisch, Dennis W. ;
Dorshimer, Gary W. ;
Rosen, Steven T. ;
Muro, Kenji ;
Gottardi-Littell, Numa R. ;
Talley, Robert L. ;
Sartor, Oliver ;
Green, David ;
Major, Eugene O. ;
Bennett, Charles L. .
BLOOD, 2009, 113 (20) :4834-4840
[8]   Successful therapy with rituximab of refractory acute humoral renal transplant rejection: A case report [J].
Celik, A. ;
Saglarn, F. ;
Cavdar, C. ;
Sifil, A. ;
Atila, K. ;
Sarioglu, S. ;
Bora, S. ;
Gulay, H. ;
Camsari, T. .
TRANSPLANTATION PROCEEDINGS, 2008, 40 (01) :302-304
[9]   ABO Blood Type Incompatible Kidney Transplantation Without Splenectomy Prepared With Plasma Exchange and Rituximab [J].
Chikaraishi, T. ;
Sasaki, H. ;
Tsutsumi, H. ;
Miyano, S. ;
Nakazawa, R. ;
Nakano, T. ;
Kitajima, K. ;
Kudo, H. ;
Takahashi, T. ;
Sato, Y. ;
Kimura, K. .
TRANSPLANTATION PROCEEDINGS, 2008, 40 (10) :3445-3447
[10]   Comparison of Clinical Outcome between High and Low Baseline Anti-ABO Antibody Titers in ABO-Incompatible Kidney Transplantation [J].
Chung, Byung Ha ;
Lee, Ja Young ;
Kang, Seok Hui ;
Sun, In O. ;
Choi, Sun Ryoung ;
Park, Hoon Suk ;
Kim, Ji-Il ;
Moon, In Sung ;
Choi, Bum Soon ;
Park, Cheol Whee ;
Kim, Yong-Soo ;
Yang, Chul Woo .
RENAL FAILURE, 2011, 33 (02) :150-158